Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ArQule says Kyowa's ATTENTION deficit won't affect MARQUEE Phase III tivantinib study

This article was originally published in Scrip

Executive Summary

Kyowa Hakko Kirin has stopped patient enrollment in the Phase III ATTENTION clinical trial in Asia for the ArQule cancer drug tivantinib due to cases of interstitial lung disease (ILD), but ArQule says the news will not impact its ongoing 1,000-patient Phase III MARQUEE trial conducted with Daiichi Sankyo in the Americas, Europe and other regions.

You may also be interested in...



J&J Quickly Advances BCMA-Targeting CAR-T As JNJ-4528 Shows 100% Response

Phase Ib data at ASH look competitive with new pivotal trial results for Bristol/bluebird’s leading BCMA CAR-T bb2121. The Phase II portion of the CARTITUDE-1 study for JNJ-4528 is fully enrolled.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Biogen’s Big Day Arrives, But Aducanumab Results Don’t Answer Key Question

Biogen presented highly anticipated data in Alzheimer’s disease at CTAD for its Phase III EMERGE and ENGAGE studies, but one major question remains unanswered: will the FDA approve the drug? 

Topics

Related Companies

UsernamePublicRestriction

Register

SC050841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel